Bioactive Sphingolipids of Cordyceps sinensis Modulate Tumor Immunity Through the SphK1 ‐Mediated Cer/ S1P Axis
Phytotherapy Research · 2026
DOI: 10.1002/ptr.70234 ↗At a glance
Journal article in Phytotherapy Research, 2026. Written by Qi-Xuan Kuang and 12 co-authors. Institution: TCM Prevention and Treatment of Metabolic and Chronic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chin…. Major MEDLINE topics: Cordyceps, Phosphotransferases (Alcohol Group Acceptor), Sphingosine, Sphingolipids. Cited 2 times so far (Crossref); 35 references. Funded by: China Postdoctoral Science Foundation, National Natural Science Foundation of China, Sichuan Province Science and Technology Support Project.
Abstract (original language)
Cordyceps sinensis is a traditional medicinal fungus known for its immunomodulatory properties. Its bioactive sphingolipids (SPLs) exhibit antitumor potential, though their mechanisms remain poorly understood. This study aimed to identify the active SPLs from C. sinensis and investigate their synergistic effects with αPD‐1 (anti‐programmed death‐1 antibody) therapy. SPLs were isolated from C. sinensis via UPLC–MS/MS‐guided purification. The antitumor efficacy and immunomodulatory synergy with αPD‐1 were assessed using a Lewis lung carcinoma (LLC) tumor‐bearing mouse model and in vitro co‐culture systems. Mechanisms involving sphingosine kinase 1 (SphK1) were explored through cellular thermal shift assays, enzymatic activity tests, surface plasmon resonance, molecular docking, and molecular dynamics simulations. The combination of SPLs and αPD‐1 enhanced antitumor immunity by promoting CD8 + T‐cell infiltration and suppressing PD‐L1 expression in the tumor microenvironment. Metabolomic and transcriptomic analyses revealed that SPLs shifted the sphingolipid balance by targeting the SphK1‐mediated ceramide/sphingosine‐1‐phosphate (Cer/S1P) axis, promoting antitumor immunity. A novel ceramide, cordysinamide A, was identified as a key bioactive constituent and shown to bind directly to SphK1 (IC₅₀ = 28.45 μM; KD = 14.4 μM), stabilizing its structure and inhibiting S1P production. This shift increased IL‐2 and IFN‐γ levels and sensitized tumors to αPD‐1 treatment. This study identifies C. sinensis ‐derived SPLs as key bioactive components that overcome αPD‐1 resistance by targeting the SphK1‐mediated Cer/S1P balance. Our findings propose a natural product‐based strategy to change immunosuppressive metabolism in non‐small cell lung cancer.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- TCM Prevention and Treatment of Metabolic and Chronic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
ORCID profiles: Qi-Xuan Kuang
Funding
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Sichuan Province Science and Technology Support Project
- Chengdu University of Traditional Chinese Medicine
Cite
APA
Kuang, Q. X., Yan, C. Y., Wang, C. Y., Hu, Y. J., Huang, Y. Q., Lei, H. R., Peng, W., Jiang, Y. F., Fu, X., Guo, D. L., Li, X. K., You, F. M., & Deng, Y. (2026). Bioactive Sphingolipids of Cordyceps sinensis Modulate Tumor Immunity Through the SphK1 ‐Mediated Cer/ S1P Axis. Phytotherapy Research. https://doi.org/10.1002/ptr.70234
Vancouver
Kuang QX, Yan CY, Wang CY, Hu YJ, Huang YQ, Lei HR, et al. Bioactive Sphingolipids of Cordyceps sinensis Modulate Tumor Immunity Through the SphK1 ‐Mediated Cer/ S1P Axis. Phytotherapy Research. 2026. doi:10.1002/ptr.70234
BibTeX
@article{Kuang2026,
author = {Kuang, Qi-Xuan and Yan, Chen-Yi and Wang, Chao-Yu and Hu, Yun-Jie and Huang, Yu-Qing and Lei, Hao-Ran and Peng, Wan and Jiang, Yi-Fang and Fu, Xi and Guo, Da-Le and Li, Xue-Ke and You, Feng-Ming and Deng, Yun},
title = {Bioactive Sphingolipids of Cordyceps sinensis Modulate Tumor Immunity Through the SphK1 ‐Mediated Cer/ S1P Axis},
journal = {Phytotherapy Research},
year = {2026},
doi = {10.1002/ptr.70234}
}
EUVIMED